Market Overview

Compugen to Significantly Expand Immuno-Oncology Activitiesin 2014

Compugen (NASDAQ: CGEN) announced today that it is significantly increasing its
Pipeline Program activities in the field of immuno-oncology. The primary
purpose of the increase is to allow research and preclinical activities
for a larger number of checkpoint target and product candidates for
cancer immunotherapy to move forward in parallel. Additional objectives
include the establishment of a biomarker discovery program for certain
of the Company's checkpoint product candidates and the acceleration of
experimental validation efforts for the recently disclosed antibody drug
conjugate (ADC) target candidates for oncology.

The significant increase in immuno-oncology activities during 2014 will
impact both the target research and validation activities performed in
Israel

See full press release

Posted-In: News Guidance Offerings Contracts Management IPOs Global

 

Related Articles (CGEN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters